Although growing evidence suggests that sesn2 protects against various cardiometabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and atherosclerosis, it is unclear whether sesn2 has a beneficial effect against cardiomyopathy-related molecular events. This evidence concerns the gene SESN2 and cardiomyopathy.